Seminars in Ophthalmology最新文献_第3页

Recent Advances in Targeted Immunomodulatory Therapies for Chronic Ocular Surface Diseases. 慢性眼表疾病靶向免疫调节治疗研究进展

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-25 DOI: 10.1080/08820538.2025.2536766

Riccardo Genovese, Sara Spelta, Andrea Leonardi, Francesco Cutrupi, Pierluigi Surico, Tommaso Mori, Roberto Sgrulletta, Marco Coassin, Antonio Di Zazzo

{"title":"Recent Advances in Targeted Immunomodulatory Therapies for Chronic Ocular Surface Diseases.","authors":"Riccardo Genovese, Sara Spelta, Andrea Leonardi, Francesco Cutrupi, Pierluigi Surico, Tommaso Mori, Roberto Sgrulletta, Marco Coassin, Antonio Di Zazzo","doi":"10.1080/08820538.2025.2536766","DOIUrl":"https://doi.org/10.1080/08820538.2025.2536766","url":null,"abstract":"Purpose: To review and compare the mechanisms of action, clinical efficacy, and safety profiles of topical immunosuppressive and immunomodulatory agents for the management of chronic ocular surface diseases.Methods: A comprehensive review of the literature was conducted using PubMed, Scopus, and Web of Science databases. Peer-reviewed clinical trials, observational studies, case series, and meta-analyses from 1960 to 2024 were included. Studies were selected based on their investigation of the efficacy and safety of topical therapies for chronic ocular surface diseases. Systemic therapies and non-ocular conditions were excluded.Results: Corticosteroids remain effective in controlling acute inflammation but are associated with significant adverse effects, particularly with long-term use, including elevated intraocular pressure, cataract formation, and infection risk. In contrast, targeted immunomodulators such as cyclosporine, tacrolimus, lifitegrast, tofacitinib, and reproxalap provide more selective modulation of the immune response. These agents have demonstrated favorable tolerability and efficacy in chronic ocular surface diseases, including dry eye disease, vernal keratoconjunctivitis, and ocular GVHD. Recent advances include IL-1 receptor antagonists, JAK inhibitors, RASP inhibitors, and mitochondrial-targeted antioxidants.Conclusions: While corticosteroids are indispensable for acute management, targeted immunomodulatory therapies offer a safer and more sustainable approach for long-term treatment of chronic ocular surface inflammation. The emergence of novel topical agents supports a shift toward precision immunotherapy in ophthalmology.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-13"},"PeriodicalIF":1.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Dilemmas in Coexisting Ocular Surface Disease and Glaucoma. 眼表疾病与青光眼共存的临床困境。

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-25 DOI: 10.1080/08820538.2025.2536235

Archana Singh, Ekta Arora, Sahib Y Tuteja, Dilpreet Singh

{"title":"Clinical Dilemmas in Coexisting Ocular Surface Disease and Glaucoma.","authors":"Archana Singh, Ekta Arora, Sahib Y Tuteja, Dilpreet Singh","doi":"10.1080/08820538.2025.2536235","DOIUrl":"https://doi.org/10.1080/08820538.2025.2536235","url":null,"abstract":"Background: Ocular surface disorders (OSD) and glaucoma often co exist. Intraocular pressure lowering medications and preservatives used with them may lead to ocular surface toxicity and drug induced cicatrizing conjunctivitis (DICC). Surgical management of glaucoma helps in reducing the requirement of topical anti glaucoma drugs but, at the same time, may also disrupt the ocular surface. On the other hand, medical therapies and surgeries required for management of OSD often lead to secondary glaucoma, thereby inducing a vicious cycle.Methods: Relevant articles (English only) up to January, 2025 were searched from PubMed and summarized.Results: Our review discusses the epidemiology, various diagnostic, therapeutic and surgical aspects of this interlinked scenario in a comprehensive manner. Medical therapies (steroids) utilized for controlling inflammation in OSD and related steroid induced glaucoma, anti glaucoma medications (and their preservatives) causing OSD and their respective available alternatives have been discussed in individual sections. Similarly, glaucoma surgeries causing OSD, surgeries for OSD leading to secondary glaucoma and the surgical considerations with possible alternatives, including the novel therapies, have been reviewed. The future directions, along with the role of gut microbiome in ocular diseases and the various therapeutic agents/interventions under clinical investigations, are also explored.Conclusion: A deeper understanding of the interplay of different factors in these co-morbid conditions will help in breaking the vicious cycle induced and therefore, in offering more effective treatment. Recommendations for clinicians have been suggested to help optimize the treatment provided to this specific patient cohort of 'OSD and glaucoma'.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-11"},"PeriodicalIF":1.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microbial Keratitis in Ocular Surface Disease. 眼表病中的微生物性角膜炎。

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-24 DOI: 10.1080/08820538.2025.2535589

Meena Lakshmipathy, Anitha Venugopal, Sushmita G Shah

{"title":"Microbial Keratitis in Ocular Surface Disease.","authors":"Meena Lakshmipathy, Anitha Venugopal, Sushmita G Shah","doi":"10.1080/08820538.2025.2535589","DOIUrl":"https://doi.org/10.1080/08820538.2025.2535589","url":null,"abstract":"Purpose: Although microbial keratitis is a known complication in eyes with chronic ocular surface disease, literature on this subject is scarce. The primary objective of this review is to describe the various aspects of microbial keratitis in ocular surface disease, with an emphasis on a better understanding of risk factors, causative organisms, antimicrobial therapy, and prevention.Methods: The literature was reviewed in detail using multiple keywords and articles describing microbial keratitis in eyes with limbal stem cell deficiency, Stevens-Johnson syndrome, mucous membrane pemphigoid, keratoconjunctivitis sicca, meibomian gland dysfunction, post-chemical injury, and other common ocular surface pathologies.Results: Common risk factors identified include dry eyes, use of topical corticosteroids, soft contact lens wear, and eye lash abnormalities such as trichiasis and distichiasis. Gram-positive bacteria have been reported to be the most common causative agents. Sensitivity to Vancomycin was the highest among the gram-positive isolates. Non- healing or persistent epithelial defects or slowly healing epithelial defects were the most common complications in these eyes, warranting amniotic membrane grafting for faster epithelial healing.Conclusion: Patients must be kept under regular monitoring, and indiscriminate use of topical antibiotics and corticosteroids must be avoided. Adequate patient education must be provided to enable patients to recognize warning signs early and seek immediate medical attention.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lacrimal History - Part 25: Doyens of Dacryology Series - The Anatomical Treatises of Johann Christian Rosenmüller (1771-1820). 泪史-第25部分：泪学系列的几十年-约翰·克里斯蒂安·罗森姆勒（1771-1820）的解剖论文。

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-23 DOI: 10.1080/08820538.2025.2538311

Mohammad Javed Ali

引用次数: 0

Lacrimal History - Part 42: Doyens of Dacryology Series - François Codère (1952-) Jane Madeleine Olver (1954-), and David Irving Silbert (1962-). 泪史-第42部分：泪学系列的作者-弗朗索瓦·科迪斯（1952-）、简·玛德琳·奥尔弗（1954-）和大卫·欧文·希尔伯特（1962-）。

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-18 DOI: 10.1080/08820538.2025.2535094

Mohammad Javed Ali

引用次数: 0

Oral Mucosa in Boston Keratoprosthesis Surgery: Innovative Approaches for Complex Cases. 波士顿角膜移植手术中的口腔黏膜：复杂病例的创新方法。

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-15 DOI: 10.1080/08820538.2025.2530550

Jonathan Paul Lacanilao, Clara Alvarez de Toledo, Ma Dominga Padilla, María Fideliz De la Paz

{"title":"Oral Mucosa in Boston Keratoprosthesis Surgery: Innovative Approaches for Complex Cases.","authors":"Jonathan Paul Lacanilao, Clara Alvarez de Toledo, Ma Dominga Padilla, María Fideliz De la Paz","doi":"10.1080/08820538.2025.2530550","DOIUrl":"https://doi.org/10.1080/08820538.2025.2530550","url":null,"abstract":"Objectives: To describe the use of oral mucosa overlay in Boston Keratoprosthesis surgery as an adjunct in complex cases.Methodology: Retrospective case series on eyes that underwent Type I Boston keratoprosthesis where oral mucosa was used as an adjunct procedure.Results: 30 eyes were identified. The oral mucosa may be used as a salvaging technique for an extruded Type I Boston Keratoprosthesis. In cases of severe dry eye where osteo-odontokeratoprosthesis cannot be performed for reasons like edentulia, or patient refusal due to cosmetic reasons, the Boston Keratoprosthesis with mucosa overlay may be performed as a simpler technique. It may also be used as a primary procedure in cases where there is high risk of melt or extrusion for a Type I Boston Keratoprosthesis such as autoimmune corneal opacity, severe chemical burn, congenital aniridia. Surgery can be performed either as a single stage or in two stages, three months apart, to ensure the development of a well-vascularized pedicle flap. Lastly, the mucosa may be used as an alternative covering to a Type II Boston Keratoprosthesis allowing for better cosmesis and easier access for possible future retina or glaucoma surgery.Conclusion: The use of oral mucosa is widely accessible to corneal surgeons due to the ease of harvesting oral mucosa, and the availability of the Type I Boston KPro. The learning curve is less steeper than the modified osteo-odontokeratoprosthesis and the cosmesis is more acceptable.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-5"},"PeriodicalIF":1.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lacrimal History - Part 41: Doyens of Dacryology Series - John Vincent Linberg (1945-). 泪史-第41部分：泪学系列-约翰·文森特·林伯格（1945-）。

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-12 DOI: 10.1080/08820538.2025.2532289

Bhupendra C K Patel, Mohammad Javed Ali

引用次数: 0

Uses of Autologous Serum in Ocular Surface Diseases: A 10-Year Experience and Review of the Literature. 自体血清在眼表疾病中的应用：10年的经验和文献综述。

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-07 DOI: 10.1080/08820538.2025.2528213

Alfredo Domínguez-López, Beatriz Buentello-Volante, Norma Magaña-Guerrero, Fátima Sofía Magaña-Guerrero, Óscar Vivanco-Rojas, Enrique O Graue Hernández, Yonathan Garfias

{"title":"Uses of Autologous Serum in Ocular Surface Diseases: A 10-Year Experience and Review of the Literature.","authors":"Alfredo Domínguez-López, Beatriz Buentello-Volante, Norma Magaña-Guerrero, Fátima Sofía Magaña-Guerrero, Óscar Vivanco-Rojas, Enrique O Graue Hernández, Yonathan Garfias","doi":"10.1080/08820538.2025.2528213","DOIUrl":"https://doi.org/10.1080/08820538.2025.2528213","url":null,"abstract":"Purpose: The aim of this study was to identify the diagnoses that led to the prescription of autologous serum (AS) in a tertiary eye care center over a 10-year period and to contextualize these findings through a comprehensive review of the literature.Methods: A retrospective case series was conducted including records of patients who were prescribed AS for the first time between January 2015 and December 2024. In parallel, we analyzed more than 30 clinical studies, including randomized controlled trials and observational reports, investigating the efficacy, safety, and concentration strategies of AS in various ocular surface diseases.Results: A total of 1,108 patients were included (mean age: 60.6±15.9 years; 81% female), with most patients between 50 and 79 years old. The most frequent diagnoses included non-Sjögren dry eye (36.4%), and primary (16.3%) and secondary (6.6%) Sjögrenös syndrome-related dry eye, with 20% and 30% being the most commonly prescribed concentrations. The literature supports the use of AS, particularly at a concentration of 20%, in conditions such as dry eye and Sjögren's syndrome, which is consistent with our findings.Conclusions: This integrated analysis provides valuable insight into current clinical practice and may support future decision-making in the treatment of ocular surface disease.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-8"},"PeriodicalIF":1.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lacrimal History - Part 22: Doyens of Dacryology Series - Other French Contributors: Pierre Dionis (1643-1718), Méry Jean (1645-1722), Thomas Méjan (late 18^th-Early 19th Century), Louis Lamorier (1696-1777), Roland Paul Arnaud (1657-1723), and George de La Faye (1699-1781). 泪史-第22部分：泪学系列的先驱-其他法国贡献者：皮埃尔·迪奥尼斯（1643-1718），姆姆萨姆（1645-1722），托马斯·姆萨姆萨姆（18世纪末- 19世纪初），路易斯·拉莫里耶（1696-1777），罗兰·保罗·阿诺（1657-1723）和乔治·德拉费（1699-1781）。

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-03 DOI: 10.1080/08820538.2025.2528544

Mohammad Javed Ali

引用次数: 0

Lacrimal History - Part 32: Doyens of Dacryology Series - Peter John Wormald (1959-). 泪史-第32部分：泪学系列-彼得·约翰·沃玛德（1959-）。

IF 1.9 4区医学

Seminars in Ophthalmology Pub Date : 2025-07-01 Epub Date: 2024-12-24 DOI: 10.1080/08820538.2024.2445901

Mohammad Javed Ali

引用次数: 0